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Chronic cerebral hypoperfusion, a mild ischemic condition is associated with advancing age and severity of dementia; however, no
unanimous therapy has been established to alleviate related neurological symptoms. We imposed a permanent, bilateral occlusion of the
common carotid arteries of rats (n = 18) to create cerebral hypoperfusion. A mitochondrial ATP-sensitive K+ channel opener diazoxide (DZ, 5
mg/kg) or its solvent dimethyl sulphoxide (DMSO) were administered i.p. (0.25 ml) on five consecutive days after surgery. Sham-operated
animals (n = 18) served as control for the surgery, while nontreated rats were used as control for the treatments. Three months after the onset
of cerebral hypoperfusion, the rats were tested in a hippocampus-related learning paradigm, the Morris water maze. Subsequently, the animals
were sacrificed and neurons, astrocytes and microglia were labeled with immunocytochemistry in the dorsal hippocampus. DMSO and
diazoxide dissolved in DMSO restored cerebral hypoperfusion-related learning dysfunction and prevented cyclooxygenase-2-positive neuron
loss in the dentate gyrus. Cerebral hypoperfusion led to reduced astrocyte proliferation, which was not clearly affected by the treatment.
Microglia activation was considerably enhanced by cerebral hypoperfusion, which was completely prevented by diazoxide dissolved in
DMSO, but not by DMSO alone. We conclude that diazoxide can moderate ischemia-related neuroinflammation by suppressing microglial
activation. Furthermore, we suggest that DMSO is a neuroprotective chemical in ischemic conditions, and it must be considerately used as a
solvent for water-insoluble compounds in experimental animal models.
D 2004 Elsevier B.V. All rights reserved.Theme: Disorders of the nervous system
Topic: Ischemia
Keywords: Cerebral hypoperfusion; Diazoxide; Dimethyl sulphoxide; Microglia; Spatial learning
1. Introduction reduced CBF is one of the triggers or the consequence ofThe incidence of chronic cerebral hypoperfusion increases
with advancing age and dementia [15]; moreover, some
researchers have found that decreasing cerebral blood flow
(CBF) values correlate with an increasing degree of cognitive
impairment in Alzheimer’s disease patients [26,43]. In addi-
tion, reduced CBF has been recently suggested as an indicator
for the progression of Alzheimer’s disease [14,41]. Whether0006-8993/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.brainres.2004.02.037
* Corresponding author. Tel.: +36-62-545-669; fax: +36-62-545-707.
E-mail address: farkase@anat-fm.szote.u-szeged.hu (E. Farkas).neuronal dysfunction cannot be conclusively decided, but
experimental evidence suggests that decreased CBF can lead
to cognitive impairment and neuronal injury [15].
The use of bilateral, permanent occlusion of the common
carotid arteries of rats (2VO) is a well-characterized model to
investigate the cognitive and histopathologic consequences
of chronic cerebral hypoperfusion [15]. The hippocampus
has been shown to be particularly affected because hippo-
campus-related spatial memory, neuronal and microvascular
integrity were predominantly compromised in the region
[8,15,52]. Several studies based on this model were designed
Table 1
Survival rate and the incidence of CNS lesions
Experimental group Survival
rate (%)
Unilateral
hippocampal
lesion (%)
Unilateral
cortical
lesion (%)
Nontreated SHAM 75 (6/8) 0.00 (0/6) 0.00 (0/6)
2VO 66.6 (6/9) 66.67 (4/6) 33.34 (2/6)
DMSO SHAM 100 (6/6) 0.00 (0/6) 0.00 (0/6)
2VO 50 (6/12) 16.67 (1/6) 16.67 (1/6)
Diazoxide SHAM 100 (8/8) 0.00 (0/6) 0.00 (0/6)
2VO 87.5 (7/8) 0.00 (0/6) 0.00 (0/6)
Abbreviations: bilateral carotid artery occlusion (2VO), dimethyl sulphoxide
(DMSO), sham operation (SHAM).
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sion of dementia associated with reduced CBF. For example,
pharmacological treatment with cholinesterase inhibitors im-
proved 2VO-related memory dysfunction, CBF, and cerebral
metabolism [36,49]. Administration of plant extracts gained
from Ginkgo biloba or huperzine-A also attenuated 2VO-
induced learning deficit [30,60]. Alternatively, dietary sup-
plements such as polyunsaturated fatty acids and antioxidants
could moderate 2VO-imposed learning impairment or in-
crease G-protein-coupled receptor densities in the hippocam-
pus [11,16]. In our present study, we alsomade use of the 2VO
model of cerebral hypoperfusion to test the potentially neuro-
protective effect of diazoxide (DZ), a putative, mitochondrial
ATP-sensitive potassium channel (mitoKATP) opener.
Diazoxide has proved to be neuroprotective in several
ischemia models. For instance, pretreatment with the agent
could reduce infarct volume after middle cerebral artery
occlusion in rats and mice [31,55]. Further in vivo experi-
ments have provided evidence that diazoxide preserves
NMDA-induced cortical arteriolar dilation after ischemia/
reperfusion in piglets [12]. The mechanism behind these
neuroprotective properties appears to be a selective opening
of mitoKATP because diazoxide effect can be abolished by the
mitoKATP blocker 5-hydroxydecanoate (5-HD) [24,32]. Hip-
pocampal CA1 and CA3 interneurons are richly endowed by
mitoKATP that express region-specific distribution [18]. The
activation of mitoKATP in these cells under glucose depriva-
tion proved to be neuroprotective as demonstrated in hippo-
campal slices [61]. Thus, the hippocampus appears to be a
potential target and diazoxide a promising drug to achieve
neuroprotection in chronic cerebral hypoperfusion.
Because diazoxide dissolves poorly in inorganic solvents,
dimethyl sulphoxide (DMSO) was chosen in this study to
prepare diazoxide solution. DMSO is widely used as a
solvent for water-insoluble compounds in experimental ani-
mal research, yet DMSO itself possesses several vascular and
neuroprotective properties [22,33,51]. For instance, DMSO
can suppress platelet aggregation by antagonizing vasoactive
substance release from platelets, or can scavenge neurotoxic
free radicals [22,51]. Keeping these effects in mind, we also
aimed to characterize and further explore the beneficial
properties of DMSO in experimental cerebral hypoperfusion.
Our objective in the present study was to test the
potentially neuroprotective effect of diazoxide in the 2VO
model of cerebral hypoperfusion. Our prediction was that
daily administration of the drug following carotid occlusion
had beneficial effect on behavioral and neurological out-
come. We were interested to investigate a late onset of
complex changes caused by cerebral hypoperfusion.
In order to demonstrate drug effect in our experimental
setup, we designed a Morris water maze paradigm frequently
used as a standard test to asses hippocampus-related spatial
memory function in 2VO [15]. Furthermore, we aimed to
develop a comprehensive description of cerebral histopath-
ologic changes by using neuronal, astroglial and microglial
markers, of which the latest has not yet been employed inexperimental, chronic cerebral hypoperfusion. Cyclooxyge-
nase-2 (COX-2) labeling was chosen to identify hippocam-
pal neurons involved in ischemic injury because this
inducible form of the enzyme is markedly expressed in
transient ischemia [25,37,42]. Glial fibrillary acidic protein
(GFAP) immunocytochemistry was employed to label astro-
cytes that can react by degeneration to reduced CBF in the
hippocampus [57]. Finally, OX-42 antibody known to rec-
ognize CR3 complement receptors (CD11b) on microglia
was used to identify microglial activation, which is an early
event in ischemia [1,57].2. Materials and methods
2.1. Surgery and treatment
Fifty-one male Wistar rats (210F 10 g) were used for the
study. All animal experiments were approved by the ethical
committee of the University of Szeged. Experimental cere-
bral hypoperfusion was imposed [16] on half of the animals
by permanent bilateral occlusion of the common carotid
arteries (2VO), the other half served as sham-operated
controls (SHAM). Prior to surgery, the animals were anes-
thetized by 400 mg/kg chloral-hydrate i.p., followed by 0.05
ml atropine i.m. The common carotid arteries were exposed
via a ventral cervical incision, and separated from their
sheaths and vagal nerves. Silk sutures were used for the
ligation. The same procedure was performed on the SHAM
group without the actual ligation. Survival rates for each
group are presented in Table 1.
Both groups were divided into three subgroups (n = 6)
based on postsurgical treatment. The first set of animals of
both SHAM and 2VO groups received 0.25 ml DMSO i.p.,
(SHAM–DMSO, 2VO–DMSO, respectively). The second
set of animals was treated with 5 mg/kg diazoxide [7,31]
given in 0.25 ml DMSO, i.p., (SHAM–DMSO+DZ, 2VO–
DMSO+DZ). The animals were injected on five consecu-
tive days. The first injection was applied directly after
surgery. The last set of animals received no treatment after
the operation and served as controls (SHAM–nontreated,
2VO–nontreated). The final composition of the experimen-
tal groups is presented in Table 1.
Fig. 1. Learning curves plotted of the Morris maze spatial orientation test.
Statistic F values are based on a two-way repeated measurement ANOVA
model (*p< 0.05). Individual days were analyzed with ANOVA and LSD
post hoc test (*p< 0.05). (*) indicates difference between SHAM–
nontreated and 2VO–nontreated, (#) stands for the difference between
2VO–nontreated and 2VO–DMSO+DZ. Abbreviations: bilateral carotid
artery occlusion (2VO), dimethyl sulphoxide (DMSO), diazoxide (DZ),
sham operation (SHAM).
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Eleven weeks after surgery, the animals were trained in
the Morris water maze [11]. The water maze consisted of a
polyester circular pool (diameter: 160 cm, height: 35 cm)
filled with water (22 jC), which was made opaque by milk
so that the rats were unable to see an underwater platform.
The hidden platform was submerged 2 cm below water
surface. The water tank was located in an experimental
room with various extra maze cues to enable the rats to learn
the location of the platform. All rats performed two trials per
day with a constant intertrial interval of 4 h, for five
consecutive days. The animals were placed in the water at
one of four starting quadrant points, which was varied
randomly over the trials. The rats were given 2 min to find
the platform and sit on it for 15 s. Rats that failed to find the
location within the given time were guided to the platform
and were allowed to stay on it for 15 s. Swimming paths
were recorded by a computerized video imaging analysis
system (EthoVision, Noldus Information Technology BV,
Wageningen, The Netherlands). At each trial, escape laten-
cy, and swimming distance traveled before reaching the
platform were analyzed.
2.3. Immunocytochemistry
Ten days after the Morris water maze experiments, the
animals were anaesthetized with an overdose of pentobar-
bital, and perfused transcardially with 100 ml saline fol-
lowed by 400 ml 3.5% paraformaldehyde and 0.5% picric
acid in 0.1 M phosphate buffer (PB, pH 7.4). The brains
were removed, one hemisphere was postfixed in the same
solution for up to 1 h, and then stored in 0.1 M PB. Six
brains per group were processed for immunocytochemical
investigation.
Free floating coronal sections at the level of the hippo-
campus were cut at 20-Am thickness on a cryostat. COX-2
labeling was performed on the first set of sections as
follows. First, endogenous peroxidase activity was blocked
with 0.3% H2O2. Nonspecific binding sites were covered
with 5% normal goat serum (NGS) and membrane perme-
ability was enhanced by 0.3% Triton X-100. The sections
were incubated for 2 days at room temperature (RT) in
primary antibody solution containing rabbit anti-COX-2
antibody (Cayman), 1:2000, 1% NGS, 0.3% Triton X-100
and 0.1% sodium azide in 0.01 M PBS (pH 7.4). Next, the
sections were rinsed and preincubated in 5% NGS for 1 h.
Incubation was performed in goat anti-rabbit biotinylated
IgG (Santa Cruz) for 4 h at RT. Finally, the signal was
amplified by an ABC–Avidin Kit (1:400) (Vector) for 2 h at
RT. Color reaction was developed by diaminobenzidine
(DAB) and H2O2.
A second set of sections was immunocytochemically
stained for glial fibrillary acidic protein (GFAP) to visualize
astrocytic proliferation. Briefly, sections were treated with
0.3% H2O2 in PBS, and preincubated in 5% normal sheep
E. Farkas et al. / Brain R254serum (NShS). The samples were then incubated in a
primary antibody solution containing mouse anti-GFAP
antibody (Sigma), 1:200, 1% NShS, and 0.3% Triton X-
100 in 0.01 M PBS, overnight at 37 jC. The secondary
antibody solution consisted of sheep anti-mouse biotiny-
lated IgG (Jackson), 1:200, and 0.3% Triton X-100 in 0.01
M PBS. Finally, the sections were incubated in HRP-
Streptavidine (Zymed), 1:200, and color reaction was con-
ventionally developed with DAB and H2O2.
To detect and analyze microglial activation over the
hippocampal areas, OX-42 antibody was used on a third
set of sections. The procedure started with washing and
pretreating the sections with 0.5% Triton X-100 and 3%
H2O2 in 0.01 M PBS, followed by preincubation in 20%
normal swine serum (NSS) and 0.5% Triton X-100 in 0.01
M PBS for 1 h. The sections were incubated in a primary
antibody solution containing biotinylated mouse anti-
CD11b antibody (OX-42, Serotec), 1:500, 20% NSS, and
0.03% mertiolate in 0.01 M PBS, overnight at RT. Next, the
sections were rinsed, and incubated in a solution of STA-
PER (Jackson), 1% NSS, and 0.03% mertiolate in 0.1 M
Tris-buffer for 1 h at RT. Finally, the color reaction was
developed by Ni-DAB and H2O2. All sections were
mounted on gelatin-coated microscopic slides, air-dried,
dehydrated and coverslipped with DPX.
2.4. Analysis
Percentual surface area of GFAP-positive astrocytes was
quantified in the dorsal hippocampus by using a Quantimet
E. Farkas et al. / Brain Research 1008 (2004) 252–260 255Q-600HR computerized image analysis system (Leica,
Cambridge, UK) with a 469.4-nm emission filter [20].
Briefly, three consecutive coronal sections with a standard
distance of 160 Am, starting at Br. 3.60 mm [46] were
selected for the analysis. Hippocampal regions of interest
were manually delineated at 10 magnification, after
background subtraction and gray scale threshold determi-
nation. The area covered by GFAP-positive astrocytes was
computed as percentage of the total area delineated.
Measurements of the three sections per animal wereFig. 2. Cyclooxygenase-2 enzyme (COX-2) immunocytochemistry in rat hippoc
preserved neurons, respectively. Significance values were obtained by Student T-tes
dentate gyrus inner granular cells (arrowheads are pointing at a few labeled ne
sulphoxide (DMSO), diazoxide (DZ), sham operation (SHAM).averaged, and the average was used for further statistical
analysis.
COX-2-labeled neuron counting was performed at 20
magnification with the help of an ocular mesh with 1600-
Am2 holes. Three consecutive coronal sections with a
standard distance of 160 Am, starting at Br.  3.60 mm
[46] were examined. COX-2-positive neurons were counted
in the CA3 stratum (str.) pyramidale and the dentate gyrus
(DG) inner and outer str. moleculare on an average surface
of 0.018 mm2 in each region. Regional cell counts of threeampus. Panels A and B show neuronal density and COX-2 expression of
t (*p< 0.05). Panels C, D and E demonstrate COX-2-positive neurons in the
urons). Abbreviations: bilateral carotid artery occlusion (2VO), dimethyl
E. Farkas et al. / Brain Research 1008 (2004) 252–260256sections per animal were averaged, and the average was
used for further statistical analysis.
The optical density of COX-2-positive neurons was
measured by using a Quantimet Q-600HR computerized
image analysis system (Leica). The same sections used for
COX-2-labeled cell counting were analyzed again, at 10
magnification. Following background subtraction and gray
scale threshold determination, COX-2-positive neurons
were automatically delineated by the program, and relative
optical density was computed based on a standard gray
scale. As done previously, values of three sections per
animal were averaged, and this value was used for further
statistical analysis.
Quantification of the surface covered by OX-42 immu-
noreactive microglia was performed in a similar manner to
GFAP-labeled sections on a computerized image analysis
system (Olympus BX50, DP50; software: ImagePro Plus,
Media Cybernetics).
The Morris maze test results were statistically analyzed
by a two-way repeated measurement model followed by
LSD post hoc test of the program SPSS. Individual day
comparisons were performed by a univariate model and
LSD post hoc analysis of SPSS. GFAP and OX-42 immu-Fig. 3. Microglial activation in the rat hippocampus CA3 region labeled with OX
image from a 2VO non-treated animal. C: image from a 2VO, DMSO-treated anim
10 magnification. Abbreviations: 2VO: bilateral carotid artery occlusion, DMSO
rad: str. radiatum, SHAM: sham-operation.nocytochemical results were statistically analyzed with two-
way ANOVA followed by LSD post hoc test.3. Results
Spatial learning curves obtained in the Morris maze test
(Fig. 1) demonstrated that experimental cerebral hypoper-
fusion induced a marked decrease in learning performance
(**p < 0.002). Moreover, hardly any day-to-day improve-
ment was observed in the nontreated 2VO group over the
5-day training period. Daily comparison of groups revealed
that the nontreated 2VO animals’ memory capacity was
significantly worse than their respective SHAM controls
specifically on days 2, 3, and 5. Conversely, either DMSO
or DMSO+DZ treatment improved learning of 2VO rats
compared to the nontreated 2VO group, (*p < 0.040 and
**p< 0.007, respectively). On the other hand, the agents
did not affect the performance of SHAM animals. Further-
more, statistical analysis of the daily performance showed
significant improvement only in the DMSO-DZ treated
2VO rats compared to the nontreated 2VO group on days
2, and 3.-42 immunocytochemistry. A: image from a SHAM non-treated animal. B:
al. D: image from a 2VO, DMSO+DZ-treated animal. Images were taken at
: dimethyl sulphoxide, DZ: diazoxide, or: str. oriens, pyr: str. pyramidale,
Fig. 4. Quantitative analysis of OX-42-positive microglial activation. A:
hippocampus CA1 region. B: hippocampus CA3 region. C: hippocampus
dentate gyrus. Statistic F values are based on a two-way ANOVA model
(*p<0.05). Abbreviations: 2VO: bilateral carotid artery occlusion, DMSO:
dimethyl sulphoxide, DZ: diazoxide, SHAM: sham-operation.
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2VO without postoperative treatment induced hippocampal
and cortical lesions (in 66.67% and 33.34% of the animals,
respectively). DMSO application reduced, while DMSO+
DZ completely abolished the occurrence of the lesions
(Table 1).
COX-2 immunocytochemistry in the dorsal hippocampus
labeled neurons in the stratum pyramidale, the hilus and
granular cells of the inner stratum moleculare of the dentate
gyrus (DG-iml) (Fig. 2). The outer stratum moleculare of the
DG contained only very few, scattered labeled neurons. Cell
counting revealed loss of about 50% of COX-2-positive
neurons in the nontreated 2VO group specifically in theDG-iml. Both DMSO and DMSO+DZ treatments prevented
neuronal loss in the region (Fig. 2A). Optical density
measurements showed that the surviving cells expressed an
unaltered amount of COX-2 (Fig. 2B).
Glial fibrillary acidic protein (GFAP) immunoreactive
astrocytes were present in all hippocampal regions and in
all experimental groups. The area covered by astrocytes
showed a similar tendency to COX-2-positive neuron count-
ing in that astrocytic proliferation was reduced in 2VO
compared to SHAM. However, no clear effect of the treat-
ments could be established (data not shown).
OX-42 positive activated microglia were scarce in the
hippocampus of SHAM animals (Fig. 3A), while a dense
staining could be observed in all hippocampal areas in the
nontreated and DMSO-treated 2VO groups (Fig. 3B and C).
On the other hand, DMSO+DZ but not DMSO alone
diminished OX-42-positive microglia in 2VO rats (Fig.
3D). Quantitative analysis demonstrated that 2VO increased
microglia activation from two to three times in the CA1,
CA3 and DG molecular layers in the nontreated and DMSO-
treated 2VO animals. The increase was statistically signif-
icant in the CA1 region (*F = 4.477). Application of
DMSO+DZ but not DMSO alone reduced microglia acti-
vation to SHAM control level in all investigated regions, but
the preventive effect of DMSO+DZ was statistically sig-
nificant only in the CA3 area (*F = 4.097) (Fig. 4).4. Discussion
The novel findings of this study are the following.
Chronic administration of DMSO following 2VO can mod-
erate ischemia-related memory failure, and diazoxide in
concert with DMSO can virtually prevent memory dysfunc-
tion. In a similar way, DMSO can confine, and diazoxide
applied in DMSO can completely diminish macroscopic
hippocampal and cortical lesions. Furthermore, DMSO
alone is sufficient to prevent COX-2-positive neuron loss
in the DG. Finally, diazoxide, but not DMSO alone can
attenuate microglia activation in the hippocampus.
Cerebral hypoperfusion created by 2VO has been repeat-
edly described to cause spatial memory dysfunction [8,11,
15,39,45], and apoptotic neuronal death in the hippocampus
of rats [6,19,40]. Similarly, our Morris maze experiment
reproduced earlier observations that chronic 2VO causes
spatial memory impairment [8,15,39,45]. On the other hand,
DMSO, and particularly DMSO +DZ restored learning
skills to nearly SHAM level. To the best of our knowledge,
the effects of diazoxide on learning and memory have not
yet been tested. In addition, only one prior study attempted
to identify the potentially beneficial effect of DMSO on
spatial learning skills, but in that study DMSO was not
administered alone but was combined with fructose 1,6-
diphosphate [10].
In addition, our examination of rat brains following 3
months 2VO revealed macroscopic hippocampal and corti-
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can very well arise from acute ischemic strokes as reported
by early studies on the 2VO model, and also correlate with
the regional distribution (hippocampus and neocortex), and
ratio of affected animals (35–65%) in previous experiments
[21,34,50]. Chronic treatment with DMSO reduced, while
DMSO +DZ abolished, such ischemic lesions. Because
DMSO can improve hemodynamic variables and CBF
[23,28,59] in addition to its known free radical scavenger
properties [2,51], an increased flow or reduced concentra-
tion of free radicals may underlie the preventive effect of the
agent. Our observation also supports the data that DMSO
could reduce infarct volume in focal cerebral ischemia
[47,54]. Diazoxide was also found to be neuroprotective
in ischemia–reperfusion brain injury [55]. Therefore, the
cumulative effect of DMSO and diazoxide could be respon-
sible for the complete prevention of lesions. Furthermore,
such a protective action accomplished by the drugs corre-
sponds with the treatment-related improvement in spatial
learning skills demonstrated in our study.
The distribution and temporal aspects of COX-2 expres-
sion have been well characterized in the hippocampus after
transient but not permanent forebrain ischemia [25,37,44].
The enzyme was suggested to promote neuronal death
because selective COX-2 inhibitors could prevent ischemic
injury in the hippocampus and other brain areas [13,37,42].
In our permanent cerebral hypoperfusion model, the pattern
of COX-2-positive neurons in the hippocampal CA3 and
DG appeared to be very similar to that seen with in situ
hybridization 3–4 days postischemia, following 5–20 min
global ischemia–reperfusion [25,37]. However, the labeling
was also present in SHAM animals in our studies as well as
other studies [37]. Thus, the data here strongly support the
assumption that the acute onset of ischemia rather than
chronic cerebral hypoperfusion or neuroinflammation is the
condition that induce neuronal COX-2 expression. Further-
more, we detected a drop in COX-2-positive neuron density
in the DG inner granular cells in untreated 2VO rats, which
was not accompanied by altered COX-2 expression in
surviving cells. Because COX-2 had been expected to be
upregulated in ischemia, the lower number of labeled
neurons compared to SHAM control might indicate neuro-
nal death in the COX-2 producing cell population. Both
DMSO and DMSO+DZ treatments prevented neuronal loss
to an equal degree, which suggests that DMSO administra-
tion was sufficient to preserve neuronal integrity in the DG.
We found reduced astrocytic proliferation in 2VO rats,
which corresponds with a previously described dynamics of
astrocytic reaction in the 2VO model. In transient 2VO, no
change was detected in astrocyte number up to 2 weeks in
case of a 5-min occlusion, but a gradual degeneration and
loss of GFAP-positive astrocytes were seen with the longer
duration of the ischemic period or survival time [57].
Because our samples were obtained 3 months after the onset
of permanent 2VO, the decline of GFAP signal could be due
to a similar, progressive loss of astrocytes. Such degenera-tion of astrocytes can have serious functional consequences
because an interaction between astrocytes, neurons and the
cerebral microcirculation is essential to maintain neural
energy metabolism and synaptic plasticity [3–5].
Finally, microglial activation was remarkably augmented
by 2VO, which could be completely prevented only with
DMSO+DZ, and not with DMSO alone. Microglia acti-
vation is an early response in the neuroinflammatory
reaction to ischemia and was repeatedly detected with
OX-42 immunocytochemistry in the hippocampus during
the acute phase of ischemia [1,38,57]. However, there is no
clear data on microglial reaction in chronic cerebral hypo-
perfusion models. Our results here show that microglial
activation persists over a long period of time after the onset
of chronic ischemia, which may suggest an ongoing neuro-
inflammatory process that accompanies chronic cerebral
hypoperfusion.
Microglia may serve as part of regenerative processes by
scavenging necrotic tissue, but can also promote delayed
neuronal damage by generating cytotoxic agents, such as
proinflammatory cytokines [27,56]. Consequently, the lower
activation state of microglia due to DMSO+DZ in our
study may be interpreted in two alternative ways. The
treatment may have confined neuronal damage that would
recruit microglia to clean up necrotic debris. On the other
hand, microglia activation itself could have been directly
inhibited, which would implicate delayed neuroprotection
via the restricted production of cytotoxic compounds. We
believe the latter is more probable because neuronal damage
that recruits microglia is an early event in stroke, and our
samples were obtained 3 months after the onset of ischemia.
Because DMSO+DZ limited microglia activation but
DMSO alone did not, this effect can be attributed specifi-
cally to diazoxide. The beneficial action of diazoxide on
neurons and astrocytes has been studied in detail [12,31,48],
but no such data is available on microglia. Therefore, these
findings may trigger further experiments to identify through
which pathways diazoxide can alter microglial activation,
and how exactly it may contribute to the outcome of
ischemic insults.
Based on our data, we have no direct evidence as to the
exact mechanism of DMSO and diazoxide that was respon-
sible for the improvement of behavior and neuronal integ-
rity. Yet, we speculate that the two agents achieved
neuroprotection through different, but to some extent com-
plementary pathways. DMSO has long been proposed to be
protective against ischemia by antagonizing platelet aggre-
gation and platelet-related vasoconstriction, or by neutraliz-
ing hydroxyl radicals [9,22]. Conversely, diazoxide has
recently come to the focus for mimicking ischemic precon-
ditioning by selectively opening mitochondrial KATP chan-
nels [58]. Therefore, the target of DMSO could be the
cerebral microcirculation, while diazoxide probably acted
directly on neural compartments.
In spite of its known pharmacological actions, DMSO is
frequently used as a solvent for diazoxide [17,29]. Based on
E. Farkas et al. / Brain Research 1008 (2004) 252–260 259our results, and because DMSO itself is a potent neuro-
protective chemical, an alternative method (e.g., NaOH and
saline) is recommended to dissolve diazoxide in future
studies designed for the investigation of neuroprotection
through KATP channel opening.
Finally, diazoxide in this study was used unconvention-
ally as a posttraumatic agent. Diazoxide is usually applied as
pretreatment before CNS insults because the drug is known
to mimic the effects of ischemic preconditioning [12,31,
35,53]. Our data that diazoxide (dissolved in DMSO) can be
potentially neuroprotective given in a posttraumatic manner
may open up new possibilities as to the therapeutic appli-
cation of the drug.Acknowledgements
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